Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.

Ceresoli, G., Rossi, G., Agustoni, F., Bonomi, L., Borghetti, P., Bulotta, A., et al. (2024). Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 199(July 2024) [10.1016/j.critrevonc.2023.104247].

Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach

Pagni, Fabio;Arcangeli, Stefano;
2024

Abstract

Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements. Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy. Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.
Articolo in rivista - Review Essay
Immunotherapy; Patient management; SCLC; Small-cell lung cancer;
English
1-feb-2024
2024
199
July 2024
104247
none
Ceresoli, G., Rossi, G., Agustoni, F., Bonomi, L., Borghetti, P., Bulotta, A., et al. (2024). Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 199(July 2024) [10.1016/j.critrevonc.2023.104247].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/458779
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact